| Literature DB >> 30038667 |
Yanmei Xu1, Hui Sun1, Xiangning Bai1, Shanshan Fu1, Ruyue Fan1, Yanwen Xiong1,2.
Abstract
BACKGROUND: Atypical enteropathogenic Escherichia coli (aEPEC) is regarded as a globally emerging enteropathogen. aEPECs exhibit various level of resistance to a range of antibiotics, which is increasing alarmingly. The present study investigated the antimicrobial resistance of aEPEC isolates recovered from diarrheal patients, healthy carriers, animals, and raw meats.Entities:
Keywords: Antimicrobial resistance; ESBL; Enteropathogenic E. coli; Multidrug resistance
Year: 2018 PMID: 30038667 PMCID: PMC6054294 DOI: 10.1186/s13099-018-0234-0
Source DB: PubMed Journal: Gut Pathog ISSN: 1757-4749 Impact factor: 4.181
Antimicrobial susceptibility profiles of 267 aEPEC strains isolated from different sources
| Class/antimicrobial | No. of resistant isolates from different sources (%) | Total | ||||
|---|---|---|---|---|---|---|
| Diarrheal patient (151) | Healthy carrier (32) | Animal (51) | Raw meat (33) | |||
| Penicillins | ||||||
| Ampicillin | 84 (55.6) | 15 (46.9) | 20 (39.2) | 13 (39.4) | 132 (49.4) | 0.1185 |
| Piperacillin | 71 (47.0) | 13 (40.6) | 19 (37.3) | 7 (21.2) | 110 (41.2) | 0.0484 |
| β-Lactam/β-lactamase inhibitor combinations | ||||||
| Amoxicillin–clavulanic acid | 14 (9.3) | 0 | 10 (19.6) | 3 (9.1) | 27 (10.1) | 0.0319 |
| Ampicillin–sulbactam | 24 (15.9) | 0 | 11 (21.6) | 9 (27.3) | 44 (16.5) | 0.0177 |
| Cephems | ||||||
| Cefepime | 14 (9.3) | 3 (9.4) | 0 | 0 | 17 (6.4) | 0.0396 |
| Cefotaxime | 39 (25.8) | 5 (15.6) | 1 (2.0) | 4 (12.1) | 49 (18.4) | 0.0013 |
| Ceftriaxone | 38 (25.2) | 5 (15.6) | 2 (3.9) | 3 (9.1) | 48 (18.0) | 0.0029 |
| Ceftazidime | 7 (4.6) | 1 (3.1) | 0 | 0 | 8 (3.0) | 0.2622 |
| Cefuroxime | 39 (25.8) | 5 (15.6) | 2 (3.9) | 6 (18.2) | 52 (19.5) | 0.0071 |
| Monobactams | ||||||
| Aztreonam | 20 (12.6) | 3 (9.4) | 0 | 1 (3.0) | 23 (8.6) | 0.0202 |
| Carbapenems | ||||||
| Imipenem | 0 | 0 | 0 | 0 | 0 | – |
| Meropenem | 0 | 0 | 0 | 0 | 0 | – |
| Aminoglycosides | ||||||
| Gentamicin | 57 (37.7) | 3 (9.4) | 11 (21.6) | 6 (18.2) | 77 (28.8) | 0.0019 |
| Kanamycin | 22 (14.6) | 1 (3.1) | 9 (17.6) | 7 (21.2) | 39 (14.6) | 0.1782 |
| Streptomycin | 78 (51.7) | 9 (28.1) | 20 (39.2) | 16 (48.5) | 123 (46.1) | 0.0692 |
| Tetracyclines | ||||||
| Tetracycline | 89 (58.9) | 15 (46.9) | 21 (41.2) | 21 (63.6) | 146 (54.7) | 0.0816 |
| Quinolones | ||||||
| Nalidixic acid | 62 (41.1) | 7 (21.9) | 17 (33.3) | 8 (24.2) | 94 (35.2) | 0.0866 |
| Fluoroquinolones | ||||||
| Ciprofloxacin | 8 (5.3) | 0 | 4 (7.8) | 1 (3.0) | 13 (4.9) | 0.4053 |
| Norfloxacin | 5 (3.3) | 0 | 4 (7.8) | 0 | 9 (3.4) | 0.1447 |
| Levofloxacin | 8 (5.3) | 0 | 4 (7.8) | 0 | 12 (4.5) | 0.2020 |
| Folate pathway inhibitors | ||||||
| Trimethoprim–sulfamethoxazole | 72 (47.7) | 6 (18.8) | 18 (35.3) | 9 (27.3) | 105 (39.3) | 0.0060 |
| Phenicols | ||||||
| Chloramphenicol | 11 (7.3) | 0 | 9 (17.6) | 8 (24.2) | 28 (10.5) | 0.0020 |
| Nitrofurans | ||||||
| Nitrofurantoin | 3 (2.0) | 0 | 1 (2.0) | 0 | 4 (1.5) | 0.7275 |
The distribution of multidrug resistance (MDR) strains among 267 aEPEC isolates
| No. of antimicrobial group | No. of resistant isolates from different sources (%) | Total | |||
|---|---|---|---|---|---|
| Diarrheal patient | Healthy carrier | Animal | Raw meat | ||
| 0 | 38 (25.2) | 10 (31.3) | 24 (47.1) | 7 (21.2) | 79 (29.6) |
| 1–2 | 29 (19.2) | 12 (37.5) | 7 (13.7) | 11 (33.3) | 59 (22.1) |
| ≥ 3 | 84 (55.6) | 10 (31.3) | 19 (37.3) | 15 (45.5) | 128 (47.9) |
| Total | 151 (100) | 32 (100) | 51 (100) | 33 (100) | 267 (100) |
Characteristics of 47 ESBL-producing aEPEC isolates
| Origin (no. of isolates) | Isolates | Antimicrobial resistance pattern |
|
| |
|---|---|---|---|---|---|
| CTX-M-1 group | CTX-M-9 group | ||||
| Diarrheal patients (38) | EP004 | AM, PRL, SAM, FEP, CTX, CRO, CXM, CAZ, ATM, CN, K, S, TE, NA, SXT | CTX-M-15 | CTX-M-14 | TEM-1 |
| EP008 | AM, PRL, SAM, CTX, CRO, CXM, ATM, CN, K, S, TE, NA, SXT | CTX-M-14 | TEM-1 | ||
| EP012 | AM, PRL, SAM, CTX, CRO, CXM, ATM, CN, K, S, TE, NA, SXT | CTX-M-14 | TEM-1 | ||
| EP013 | AM, PRL, SAM, CTX, CRO, CXM, ATM, CN, K, S, TE, NA, SXT | CTX-M-14 | TEM-1 | ||
| EP014 | AM, PRL, SAM, CTX, CRO, CXM, ATM, CN, K, S, TE, NA, SXT | CTX-M-14 | TEM-1 | ||
| EP017 | AM, PRL, AMC, SAM, CTX, CRO, CXM, CN, K, S, TE, NA, SXT, C | CTX-M-14 | TEM-1 | ||
| EP028 | AM, PRL, FEP, CTX, CRO, CXM, CAZ, ATM, CN, TE, NA, SXT | CTX-M-15 | TEM-1 | ||
| EP033 | AM, PRL, CTX, CRO, CXM, CN, S, TE | CTX-M-14 | TEM-1 | ||
| EP041 | AM, PRL, CTX, CRO, CXM, CN, S, SXT | CTX-M-3 | TEM-1 | ||
| EP043 | AM, PRL, CTX, CRO, CXM, ATM | CTX-M-55 | TEM-1 | ||
| EP064 | AM, PRL, CTX, CRO, CXM, CN, NA, SXT | CTX-M-3 | TEM-1 | ||
| EP074 | AM, PRL, AMC, SAM, FEP, CTX, CRO, CXM, CAZ, ATM, CN, S, TE, NA, SXT | CTX-M-15 | |||
| EP079 | AM, PRL, AMC, SAM, FEP, CTX, CRO, CXM, CAZ, ATM, CN, K, S, TE, NA, SXT | CTX-M-15 | TEM-1 | ||
| EP088 | AM, PRL, FEP, CTX, CRO, CXM, CN, S, TE, SXT | CTX-M-3 | |||
| EP103 | AM, PRL, SAM, FEP, CTX, CRO, CXM, ATM, CN, K, S, TE, NA, CIP, LEV, C, F | CTX-M-55 | CTX-M-14 | TEM-1 | |
| EP105 | AM, PRL, CTX, CRO, CXM, ATM, CN, K, S, TE, NA, CIP, LEV, SXT, F | CTX-M-65 | |||
| EP109 | AM, PRL, AMC, CTX, CRO, CXM, ATM, CN, S, NA, SXT | CTX-M-15 | TEM-1 | ||
| EP112 | AM, PRL, SAM, CTX, CRO, CXM, CN, S, TE, NA, SXT | CTX-M-14 | |||
| EP115 | AM, PRL, AMC, SAM, FEP, CTX, CRO, CXM, ATM, CN, K, S, TE, NA, CIP, LEV, SXT, C, F | CTX-M-15 | TEM-1 | ||
| EP116 | AM, PRL, AMC, FEP, CTX, CRO, CXM, CN, S, TE, NA, SXT | CTX-M-14 | TEM-1 | ||
| EP136 | AM, PRL, CTX, CRO, CXM, ATM | CTX-M-15 | |||
| EP155 | AM, PRL, CTX, CRO, CXM, CN, S, TE, SXT | CTX-M-14 | |||
| EP163 | AM, PRL, CTX, CRO, CXM, S, SXT | CTX-M-14 | |||
| EP166 | AM, PRL, CTX, CRO, CXM, TE, SXT | CTX-M-14 | TEM-1 | ||
| EP171 | AM, PRL, FEP, CTX, CRO, CXM, CAZ, ATM, CN, TE, SXT | CTX-M-55 | TEM-1 | ||
| EP176 | AM, PRL, FEP, CTX, CRO, CXM, CN, K, S, TE, NA | CTX-M-14 | TEM-1 | ||
| EP179 | AM, PRL, SAM, CTX, CRO, CXM, CN, S, TE, NA, SXT | CTX-M-14 | TEM-1 | ||
| EP180 | AM, PRL, FEP, CTX, CRO, CXM, CAZ, ATM, S, TE, NA | CTX-M-15 | CTX-M-14 | ||
| EP182 | AM, PRL, SAM, CTX, CRO, CXM, CN, K, S, TE, NA | CTX-M-14 | |||
| EP186 | AM, PRL, CTX, CRO, CXM, CN, K, S, TE, NA, CIP, NOR, LEV, SXT, C | CTX-M-14 | TEM-1 | ||
| EP187 | AM, PRL, AMC, FEP, CTX, CRO, CXM, CN, S, TE, SXT | CTX-M-3 | TEM-1 | ||
| EP191 | AM, PRL, SAM, CTX, CRO, CXM, CN, K, S, TE, SXT | CTX-M-14 | TEM-1 | ||
| EP193 | AM, PRL, SAM, FEP, CTX, CRO, CXM, CAZ, ATM, CN, K, S | CTX-M-55 | TEM-1 | ||
| EP239 | AM, PRL, AMC, SAM, CTX, CRO, CXM, CN, S, TE, NA, SXT | CTX-M-14 | TEM-1 | ||
| EP370 | AM, PRL, FEP, CTX, CRO, CXM, CN, TE, NA, SXT | CTX-M-14 | |||
| EP408 | AM, PRL, SAM, CTX, CRO, CXM, ATM, S, TE, NA, SXT | CTX-M-14 | TEM-1 | ||
| EP410 | AM, PRL, CTX, CRO, CXM, ATM, CN, NA | CTX-M-15 | |||
| EP412 | AM, PRL, CTX, CRO, CXM, TE | CTX-M-13 | |||
| Healthy carriers (5) | EP318 | AM, PRL, FEP, CTX, CRO, CXM, CAZ, ATM | CTX-M-15 | ||
| EP361 | AM, PRL, FEP, CTX, CRO, CXM, K, S, TE, NA | CTX-M-14 | |||
| EP 402 | AM, PRL, FEP, CTX, CRO, CXM, ATM, TE | CTX-M-3 | |||
| EP404 | AM, PRL, CTX, CRO, CXM, S | CTX-M-14 | |||
| EP415 | AM, PRL, CTX, CRO, CXM, ATM, TE | CTX-M-15 | |||
| Animal (1) | EP298 | AM, PRL, CTX, CRO, CXM, K, S, TE, NA, SXT, C | CTX-M-14 | ||
| Raw meat (3) | EP244 | AM, PRL, AMC, SAM, CTX, CRO, CXM, ATM, S, TE, NA, SXT, C | CTX-M-14 | ||
| EP299 | AM, PRL, CTX, CRO, CXM, K, S, TE, NA, SXT, C | CTX-M-14 | |||
| EP344 | AM, PRL, CTX, CRO, CXM, K, S, TE, C | CTX-M-14 | |||
Fig. 1Comparison of antimicrobial susceptibility profiles of ESBL-producing and non-ESBL-producing aEPEC isolates. Proportions (%) of isolates (y-axis) resistant to antimicrobial agents (x-axis) among ESBL-producing and non-ESBL-producing isolates
Resistance-related genes among 96 genome sequenced aEPEC isolates
| Phenotype of resistance (no. of isolates) | Resistance genes | No. of isolates (%) |
|---|---|---|
| Ampicillin (50) |
| 24 (48.0) |
|
| 8 (16.0) | |
|
| 3 (6.0) | |
| 8 (16.0) | ||
| 1 (2.0) | ||
| 2 (4.0) | ||
| 1 (2.0) | ||
| Tetracycline (51) |
| 27 (52.9) |
|
| 2 (3.9) | |
|
| 1 (2.0) | |
| 9 (17.6) | ||
| 5 (10.0) | ||
| Chloramphenicol (8) |
| 3 (37.5) |
|
| 5 (62.5) | |
| Trimethoprim–sulfamethoxazole (40) | 15 (37.5) | |
| 6 (15.0) | ||
| 3 (7.5) | ||
| 14 (35.0) | ||
| 2 (5.0) | ||
| 1 (2.5) | ||
| Gentamicin (33) |
| 23 (69.7) |
| 3 (9.1) | ||
| 2 (6.1) | ||
| 1 (3.0) | ||
| Streptomycin (44) |
| 4 (9.1) |
|
| 2 (4.5) | |
| 24 (54.5) | ||
| 1 (2.3) | ||
| Kanamycin (12) |
| 1 (8.3) |
|
| 3 (25.0) | |
| 2 (16.7) |